Search results
Results from the WOW.Com Content Network
Etomidate [3] (USAN, INN, BAN; marketed as Amidate) is a short-acting intravenous anaesthetic agent used for the induction of general anaesthesia and sedation [4] for short procedures such as reduction of dislocated joints, tracheal intubation, cardioversion and electroconvulsive therapy.
Pentaerythritol tetrakis(3-mercaptopropionate) is a common thiol monomer reacted with alkenes in the thiol-ene reaction to form polymeric networks. [3] Being functionalized with four thiol groups, it can react with multifunctional alkenes to form thiol-ene networks.
3-Mercaptopropionic acid (3-MPA) is an organosulfur compound with the formula HSCH 2 CH 2 CO 2 H. It is a bifunctional molecule, containing both carboxylic acid and thiol groups. It is a colorless oil. It is derived from the addition of hydrogen sulfide to acrylic acid.
The polymer is a liquid at room temperature. Solubility in water decreases rapidly with increasing molar mass. Secondary hydroxyl groups in PPG are less reactive than primary hydroxyl groups in polyethylene glycol. PPG is less toxic than PEG, so biotechnologicals are now mainly produced with PPG. [4] [5] [6]
Ethyl propionate is an organic compound with formula C 2 H 5 O 2 CCH 2 CH 3. It is the ethyl ester of propionic acid. It is a colorless volatile liquid with a pineapple-like odor. [3] Some fruits such as kiwis [4] and strawberries [5] contain ethyl propionate in small amounts.
3-Mercaptopropionitrile is the organosulfur compound with the formula HSCH 2 CH 2 CN. [1] Containing both thiol and nitrile functional groups , it is a bifunctional compound . A colorless liquid, the compound has found some use as a masked form of thiolate.
Pentaerythritol was first reported in 1891 by German chemist Bernhard Tollens and his student P. Wigand. [5] It may be prepared via a base-catalyzed multiple-addition reaction between acetaldehyde and 3 equivalents of formaldehyde to give pentaerythrose (CAS: 3818-32-4), followed by a Cannizzaro reaction with a fourth equivalent of formaldehyde to give the final product plus formate ion.
SR9009, also known as Stenabolic, is a research drug that was developed by professor Thomas Burris of the Scripps Research Institute as an agonist of Rev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA) [1] with a half-maximum inhibitory concentration (IC 50) = 670 nM for Rev-ErbAα and IC 50 = 800 nM for Rev-ErbAβ. [2]